

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
August 2, 2010**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Trius Therapeutics, Inc.

File No. 333-162945 - CF#24315

Trius Therapeutics, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on November 6, 2009.

Based on representations by Trius Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

| | |
|---------------|--------------------------|
| Exhibit 10.13 | through January 31, 2019 |
| Exhibit 10.14 | through August 31, 2013 |
| Exhibit 10.15 | through March 17, 2014 |
| Exhibit 10.16 | through June 15, 2013 |
| Exhibit 10.17 | through June 15, 2013 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Jeffrey Riedler
Assistant Director